Ann: MMJ Appoints Pharmaceutical Professionals to Drive Strategy-MMJ.AX, page-2

Suite 25, 145 Stirling Highway, Nedlands WA 6009 | PO Box 3144, Nedlands WA 6009 Phone +61(0) 8 9389 3150 | Fax +61(0) 8 9389 3199 | Email [email protected] Web www.mmjphytotech.com.au | ABN 91 601 236 417 14 June 2016 MMJ PHYTOTECH APPOINTS PHARMACEUTICAL PROFESSIONALS TO DRIVE EXPANSION STRATEGY Highlights:  Stanislav Sologubov appointed Chief Executive Officer of Satipharm Switzerland to drive European sales growth  John Hollister appointed as consultant to provide framework on pharmaceutical manufacturing across key business divisions in Canada, Israel and Switzerland  Licensing applications for Duncan and Lucky Lake production facilities progressing positively with Health Canada MMJ PhytoTech Limited (ASX: MMJ) (“MMJ” or “the Company”) is pleased to advise that it has strengthened its senior management and advisory personnel with the appointment of Stanislav Sologubov as Chief Executive Officer of Satipharm Switzerland and John Hollister as a strategic pharmaceutical consultant. The key appointments have been made as MMJ continues to advance its clinical development and pharmaceutical processing strategy, and are intended to support the Company’s ongoing evolution towards a pharmaceutical business model. As CEO of Satipharm Switzerland, Sologubov will be focused on accelerating sales of Satipharm’s medical cannabis (“MC”) consumer health products in Europe. With the mid-term goal of establishing a robust, multi-product cash flow stream to fund MMJ’s clinical development and pharmaceutical processing initiatives. Sologubov will initially focus on the rapid expansion of Satipharm Gelpell® Gastro-Resistant Microgel CBD Oral capsule sales. Furthermore, Satipharm has a robust pipeline of exclusive MC-based consumer health products which have been earmarked for near-term release to support the pharmaceutical-grade capsules, and the Company will provide additional product updates in due course. Sologubov is an international sales and marketing expert with more than 15 years’ experience working with global healthcare companies including Johnson & Johnson and Bausch + Lomb a robust track record in delivering sales growth and brings with him a wealth of industry knowledge and contacts that will play a critical role in building MMJ’s market presence in Europe. Hollister is a healthcare industry executive with more than 25 years’ experience working for large pharmaceutical, biotechnology and medical device companies. Hollister has extensive experience in all aspects of commercialisation in the healthcare industry, having recently held the position of CEO at US-based biopharmaceutical company Nemus Bioscience Inc.